Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
AstraZeneca
Dow
Boehringer Ingelheim
McKesson

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR EXELON


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Exelon

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000174 ↗ Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) Completed Novartis Phase 3 1969-12-31 This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs. placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40 countries for Alzheimer's disease to date, including all 15 member states of the European Union, New Zealand, Argentina, Brazil and Mexico. Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo. Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day) for the majority of the study. At every regular visit scheduled every three months, patients will be given basic efficacy and safety assessments. These assessments will include evaluation of adverse events, vital signs, activities of daily living, and clinical staging scales to determine if the subject may have converted to dementia.
NCT00018278 ↗ Electrophysiologic Measures of Treatment Response in Alzheimer Disease Completed US Department of Veterans Affairs Phase 4 1998-10-01 The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
NCT00018278 ↗ Electrophysiologic Measures of Treatment Response in Alzheimer Disease Completed VA Office of Research and Development Phase 4 1998-10-01 The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exelon

Condition Name

Condition Name for Exelon
Intervention Trials
Alzheimer's Disease 12
Alzheimer Disease 7
Parkinson's Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Exelon
Intervention Trials
Alzheimer Disease 20
Dementia 7
Parkinson Disease 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Exelon

Trials by Country

Trials by Country for Exelon
Location Trials
United States 112
Germany 11
China 10
Netherlands 8
Canada 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Exelon
Location Trials
California 8
Texas 8
New York 7
Florida 6
Arizona 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Exelon

Clinical Trial Phase

Clinical Trial Phase for Exelon
Clinical Trial Phase Trials
Phase 4 15
Phase 3 7
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Exelon
Clinical Trial Phase Trials
Completed 30
Terminated 6
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exelon

Sponsor Name

Sponsor Name for Exelon
Sponsor Trials
Novartis Pharmaceuticals 6
Novartis 5
ZonMw: The Netherlands Organisation for Health Research and Development 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Exelon
Sponsor Trials
Other 58
Industry 22
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Harvard Business School
McKinsey
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.